Italian Platelet Technology Assessment Study (IPTAS) aims at comparing bleeding frequency and severity after transfusion of standard platelets versus platelets prepared with two commercial pathogen reduction technologies (PRT) and to perform a proteomic analysis of standard versus PRT platelets. The two technologies will be analyzed separately. Primary endpoint: incidence of bleeding of grade 2 or greater in recipients of PRT platelets versus incidence in recipients of control (standard) platelets. Secondary endpoints: time to the first grade 2 or greater bleeding event after the first study transfusion; proportion of transfusions given to treat breakthrough bleeding; number of days with grade 2 or greater bleeding during the period of platelet transfusion support; number of platelet units transfused and total dose of platelets transfused per day of thrombocytopenic platelet support; proportion of patients with acute transfusion reactions; post-transfusion platelet count increments Observational endpoints: frequency of human leukocyte antigen (HLA) alloimmunization, frequency of clinical refractoriness to platelet transfusion with demonstrated HLA alloimmunization, frequency of clinical refractoriness to platelet transfusion that is persistent during the period of platelet support in the absence of HLA or human platelet antigen (HPA) alloimmunization Patients will be evaluated for 4 weeks after randomization.
When patient's platelet count, done in early morning every day, falls below 10000/microliter, physician in charge issues a platelet transfusion request to transfusion service. Transfusion service (which knows patient treatment arm) issues a PRT product or a standard product as indicated, typically within hours of request receipt; patient's physician identifies unit code and intended recipient's code and determines vital signs (pulse, blood pressure, body temp). Transfusion is started and completed in 30 min. Adverse reactions are monitored by ward personnel and once a day IPTAS local coordinator visits the ward, checks IPTAS patients' records, fills IPTAS forms, examines and interviews each enrolled patient and transfers filled forms to data coordinating center in Milan.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Enrollment
456
One dose of pathogen reduced platelets
One dose of standard platelets
Azienda Ospedaliera Universitaria San Martino
Genova, Italy
Fondazione Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
Azienda Ospedaliera Universitaria Federico II
Napoli, Italy
Ospedale di Padova
Padua, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
Azienda Ospedaliera Policlinico Umberto I
Roma, Italy
Ospedale di Udine
Udine, Italy
Azienda Ospedaliera Verona
Verona, Italy
Proteomics Laboratory, Università della Tuscia
Viterbo, Italy
Incidence of bleeding of grade 2 or greater in recipients of PRT platelets versus incidence in recipients of control (standard) platelets
Time frame: Within 4 weeks after randomization
Time to the first grade 2 or greater bleeding event after the first study transfusion
Time frame: Within 4 weeks after randomization
Proportion of transfusions given to treat breakthrough bleeding
Time frame: Within 4 weeks after randomization
Number of days with grade 2 or greater bleeding during the period of platelet transfusion support
Time frame: Within 4 weeks after randomization
Number of platelet units transfused per day of thrombocytopenic platelet support
Time frame: Within 4 weeks after randomization
Proportion of patients with acute transfusion reactions
Time frame: Within 4 weeks after randomization
Post-transfusion platelet count increments
Time frame: Within 4 weeks after randomization
Total dose of platelets transfused per day of thrombocytopenic platelet support
Time frame: Within 4 weeks after randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.